Pro-Inflammatory Cytokines Trigger the Overexpression of Tumour-Related Splice Variant RAC1B in Polarized Colorectal Cells
- PMID: 35326545
- PMCID: PMC8946262
- DOI: 10.3390/cancers14061393
Pro-Inflammatory Cytokines Trigger the Overexpression of Tumour-Related Splice Variant RAC1B in Polarized Colorectal Cells
Erratum in
-
Correction: Pereira et al. Pro-Inflammatory Cytokines Trigger the Overexpression of Tumour-Related Splice Variant RAC1B in Polarized Colorectal Cells. Cancers 2022, 14, 1393.Cancers (Basel). 2025 May 13;17(10):1642. doi: 10.3390/cancers17101642. Cancers (Basel). 2025. PMID: 40427229 Free PMC article.
Abstract
An inflammatory microenvironment is a tumour-promoting condition that provides survival signals to which cancer cells respond with gene expression changes. One example is the alternative splicing variant Rat Sarcoma Viral Oncogene Homolog (Ras)-Related C3 Botulinum Toxin Substrate 1 (RAC1)B, which we previously identified in a subset of V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF)-mutated colorectal tumours. RAC1B was also increased in samples from inflammatory bowel disease patients or in an acute colitis mouse model. Here, we used an epithelial-like layer of polarized Caco-2 or T84 colorectal cancer (CRC) cells in co-culture with fibroblasts, monocytes or macrophages and analysed the effect on RAC1B expression in the CRC cells by RT-PCR, Western blot and confocal fluorescence microscopy. We found that the presence of cancer-associated fibroblasts and M1 macrophages induced the most significant increase in RAC1B levels in the polarized CRC cells, accompanied by a progressive loss of epithelial organization. Under these conditions, we identified interleukin (IL)-6 as the main trigger for the increase in RAC1B levels, associated with Signal Transducer and Activator of Transcription (STAT)3 activation. IL-6 neutralization by a specific antibody abrogated both RAC1B overexpression and STAT3 phosphorylation in polarized CRC cells. Our data identify that pro-inflammatory extracellular signals from stromal cells can trigger the overexpression of tumour-related RAC1B in polarized CRC cells. The results will help to understand the tumour-promoting effect of inflammation and identify novel therapeutic strategies.
Keywords: RAC1; colorectal cancer; inflammation; interleukin; macrophage; signal transduction.
Conflict of interest statement
The authors declare no conflict of interest.
Figures







Similar articles
-
The Roles of RAC1 and RAC1B in Colorectal Cancer and Their Potential Contribution to Cetuximab Resistance.Cancers (Basel). 2024 Jul 6;16(13):2472. doi: 10.3390/cancers16132472. Cancers (Basel). 2024. PMID: 39001533 Free PMC article. Review.
-
B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival.Gastroenterology. 2008 Sep;135(3):899-906. doi: 10.1053/j.gastro.2008.05.052. Epub 2008 May 22. Gastroenterology. 2008. PMID: 18602919
-
Ibuprofen inhibits colitis-induced overexpression of tumor-related Rac1b.Neoplasia. 2013 Jan;15(1):102-11. doi: 10.1593/neo.121890. Neoplasia. 2013. PMID: 23359345 Free PMC article.
-
RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.Eur J Cancer. 2014 Jul;50(11):1973-81. doi: 10.1016/j.ejca.2014.04.019. Epub 2014 May 12. Eur J Cancer. 2014. PMID: 24833563
-
Role of Inflammation in the Development of Colorectal Cancer.Endocr Metab Immune Disord Drug Targets. 2021;21(1):77-90. doi: 10.2174/1871530320666200909092908. Endocr Metab Immune Disord Drug Targets. 2021. PMID: 32901590 Review.
Cited by
-
Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder.Biomedicines. 2022 Jun 8;10(6):1357. doi: 10.3390/biomedicines10061357. Biomedicines. 2022. PMID: 35740379 Free PMC article. Review.
-
Correction: Pereira et al. Pro-Inflammatory Cytokines Trigger the Overexpression of Tumour-Related Splice Variant RAC1B in Polarized Colorectal Cells. Cancers 2022, 14, 1393.Cancers (Basel). 2025 May 13;17(10):1642. doi: 10.3390/cancers17101642. Cancers (Basel). 2025. PMID: 40427229 Free PMC article.
-
Low expression of SEMA4D as a potential predictive molecular marker of poor survival in patients with melanoma combined with liver cancer.Oncol Lett. 2023 Mar 7;25(4):160. doi: 10.3892/ol.2023.13746. eCollection 2023 Apr. Oncol Lett. 2023. PMID: 36936030 Free PMC article.
-
The Roles of RAC1 and RAC1B in Colorectal Cancer and Their Potential Contribution to Cetuximab Resistance.Cancers (Basel). 2024 Jul 6;16(13):2472. doi: 10.3390/cancers16132472. Cancers (Basel). 2024. PMID: 39001533 Free PMC article. Review.
-
The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers?Cancers (Basel). 2022 May 30;14(11):2709. doi: 10.3390/cancers14112709. Cancers (Basel). 2022. PMID: 35681689 Free PMC article. Review.
References
-
- Velho S., Moutinho C., Cirnes L., Albuquerque C., Hamelin R., Schmitt F., Carneiro F., Oliveira C., Seruca R. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer. 2008;8:255. doi: 10.1186/1471-2407-8-255. - DOI - PMC - PubMed
-
- Jordan P. Colorectal Cancer Subtypes—The Current Portrait. In: Jordan P., editor. Targeted Therapy of Colorectal Cancer Subtypes. Volome 1110. Springer International Publishing; Cham, Switzerland: 2018. pp. 1–6. Advances in Experimental Medicine and Biology. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous